subcutaneous

Pharma

GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

With checkpoint inhibitors like Keytruda and Opdivo now sporting subQ formulations, GSK wants to ensure its own PD-1 drug doesn’t miss out on the action.

Fraiser Kansteiner Jan 20, 2026 2:26pm

Roche's bispecific Lunsumio goes subcutaneous

Dec 22, 2025 10:15am

Argenx cans Vyvgart trials in thyroid eye disease over futility

Dec 15, 2025 10:00am

Halozyme CEO targets new deals as IRA uncertainty subsides

Oct 14, 2025 9:40am

puzzle pieces merger and acquisition business concept

Halozyme buys Elektrofi for up to $900M

Oct 1, 2025 2:36pm

Merck scores FDA approval for subcutaneous Keytruda

Sep 19, 2025 4:54pm